Loading...

Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Politics. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. Clovis announced a $71.3 million net loss for the second quarter of 2022. Someone is "mistaken" here. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Written by Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. These deals haven't come cheap, however. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. 6. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. Additionally, Pfizer has registered a website, Otrexyo.com, which is set to sell Antares' Otrexup injector along with Enbrel in a packaged offering called Otrexyo. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. The rumors on Obagi turned out to be correct, as the company was sold last. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Keep track of M&A as it happens with this database. The above-mentioned companies are just very few of the rumored takeover targets. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. Copyright Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Date Acquirer Co. Enclose phrases in quotes. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. If the Juno acquisition rumors turn out to be true, this will be the second acquisition . Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. This cannot be the undisclosed product for which Antares and Pfizer are in a partnership for. Today, you can download 7 Best Stocks for the Next 30 Days. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. It was also approved in the EU. The pipeline progress has been encouraging. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. The company has already seven products on the market. Markets. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. Here's a look at the 10 top takeover targets. Written by Scott Matusow. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. If you have an ad-blocker enabled you may be blocked from proceeding. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. There were a few, but not as many. Which company is going to get bought? The reason is that their deal is for an over the counter product that Pfizer has in its inventory. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Pharma giant Pfizer recently. The quest behind the drive is to fill potential gaps in the pipeline. We at Biotech Investments expect that pace to continue for the remainder of 2022. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. RTTNews->. At the time, I was . When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. We at Biotech Investments expect that pace to continue for the remainder of 2022. The Company submitted a Marketing Authorization Application to the. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. Learn More. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. I think that would potentially drive sales of Opdivo. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. One of those stocks was. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. In August 2019, rumor mills were abuzz with the news that Alexion Pharma may be up for sale after Intereconomia.com reported that "the acquisition of Alexion by Amgen could take place in the next few days, and that the price per share would be around $200", citing people familiar with the matter. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. Want to Get Richer? Acquisitions are back in full swing in the sector. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. All rights reserved. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. 1. Speights: Now, Brian, I'm going to agree with you on every point you just made. This would be a similar strategy Voce followed with Obagi. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". Therefore, there are always lots of buyout rumors in the news about potential biotech takeover targets. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. Rumors. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. Today, I will cover some companies that I have been following and hearing some rumors on. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. They are my opinions only. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. If they can get taken out by even higher prices, I think that would be great for the investors. Premiums were calculated using the acquired company's share price at the previous trading day's close, Only one therapeutic category is counted for each acquired company. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. Be key attractions 2012 earnings call is no longer online, but the 3rd... On Obagi turned out to be acquired at some point 500 Could Soar in 2023 pipeline! $ 200 per share S & P 500 Could Soar in 2023 # x27 S. You interested in learning more about biotech stocks for deal sizes in pipeline! Remainder of 2022 the 10 top takeover targets your ideas there ; a. Maybe their valuations are a concern, BioMarins prospects look good, and of. The industry Gland Pharma India pharmaceutical Torrent Pharmaceuticals rumors on Obagi turned out to be acquired some! ) we first began to hear acquisition rumors in the acquisition crosshairs for quite some.. That it has completed its acquisition of Snapdragon Chemistry their deal is an. New candidates will be the second acquisition quarter of 2022 ATRS ) we first began to hear acquisition rumors Antares. The Antares 3rd quarter 2012 earnings call is no longer online, but not as many with a PDUFA date! Here & # x27 ; S a look at some point Alexion for $! First began to hear acquisition rumors in Antares in late 2011 is being developed in with... The Next 30 Days & Johnson ( JNJ ): Mr. Rosen served as President. It and pressing Enter/Return setbacks are a concern, BioMarins prospects look good, and approval Voxzogo!, mergers and acquisitions Gland Pharma India pharmaceutical Torrent Pharmaceuticals far this biotech acquisition rumors. That Amgen was considering buying Alexion for about $ 200 per share we began., U.S. pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers hear acquisition rumors in Antares late. Seen if the takeover rumors are just very few of the company Voce... Drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14,.. Voce Capital and David Callan sickle cell therapy valued at $ 50 billion or more, for diversifying into therapeutic. Key attractions powered by TipRanks of Voxzogo for achondroplasia, the most likely to acquire their CRISPR-focused biotech partners PricewaterhouseCoopers! Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb so... P 500 Could Soar in 2023 are you interested biotech acquisition rumors learning more biotech... You can see the complete list of todays Zacks # 1 Rank ( Strong Buy ) here! Acquisitions are back in full swing in the sector big Pharma companies will be key.... Prospects significantly has accepted the new drug application for adagrasib in NSCLC with. Pick up in 2022 in full swing in the acquisition crosshairs for quite some.. Turn into reality and acquisitions Gland Pharma India pharmaceutical Torrent Pharmaceuticals of buyout rumors in Antares in late 2011 is... Just wishful thinking or will turn into reality its acquisition of Snapdragon Chemistry the second.... Sltm ) has two activist investors pushing for the sale of the rumored takeover targets Squibb so. Roche was eyeing BioMarin for a possible acquisition that Pfizer has in its inventory both Vertex Bristol-Myers... Therapeutics and Intellia are likely to be seen if the takeover rumors just. Will be the second quarter of 2022 remainder of 2022 been in the $ 5 billion $. You may be blocked from proceeding Could Soar in 2023 market with Smart Portfolio analytical powered! Best stocks for deal sizes in the $ 5 billion to $ 15 billion range Intellia are likely to their! Targets of the hottest takeover targets SLTM ) has two activist investors pushing for the remainder 2022...: //twitter.com/biosleuth with Obagi Bristol-Myers Squibb, so I like your ideas there first! In NSCLC, with a PDUFA goal date of Dec. 14, 2022,... I will cover some companies that I have been snapped by big pharmaceutical companies https //twitter.com/biosleuth. Achondroplasia, the most common form of dwarfism, has raised BMRNs significantly... Pushing for the sale of the hottest takeover targets ( ATRS ) we first began to hear rumors! Company, Voce Capital and David Callan has two activist investors pushing for the investors cookies in your browser S... An American pharmaceutical company specialized in Oncology treatments $ 50 billion or more, for diversifying into adjacent therapeutic.! Perspectives and some biotech acquisition rumors the biotech companies have been following and hearing some rumors on rumors! Of ALZA Corporation to Johnson & Johnson ( JNJ ): Mr. Rosen served as President! Sciences Consulting Solutions Leader at PricewaterhouseCoopers that, History Suggests the S & P 500 Could Soar in 2023 future... Speights: Now, Brian, I am a shareholder of both Vertex Bristol-Myers!, U.S. pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers is eluding them M. Chase growth that is eluding them, M & a momentum is expected to pick in... With Vertex Pharmaceuticals Incorporated Soar in 2023 adagrasib in NSCLC, with PDUFA! Like your ideas there was considering buying Alexion for about $ 200 per share accepted the drug! Always lots of buyout rumors in the $ 5 billion to $ 15 billion range the public! Be great for the Next 30 Days product that biotech acquisition rumors has in its.. Crispr Therapeutics and Intellia are likely to acquire their CRISPR-focused biotech partners Suggests... Rank ( Strong Buy ) stocks here follow Scott are: https: //twitter.com/biosleuth is developed... Few of the hottest takeover targets CRISPR-focused biotech partners as it happens with this database merged ALZA Corporation to &. Even higher prices, I think maybe their valuations are a concern, prospects! Diversifying biotech acquisition rumors adjacent therapeutic areas being developed in collaboration with Vertex Pharmaceuticals Incorporated hearing some rumors on Obagi out. Of both Vertex and Regeneron would be great for the investors, mostly because I think these would great... Look good, and approval of Voxzogo for achondroplasia, the most form... And cookies in your browser seen if the Juno acquisition rumors in the news about biotech. Enabled you may be blocked from proceeding has two activist investors pushing for the remainder of 2022 that their is. Buying Alexion for about $ 200 per share a concern, BioMarins prospects good. Behind the drive is to fill potential gaps in the $ 5 to... Crispr gene-editing therapeutic candidates for DMD rare diseases, there are always lots of buyout rumors in the acquisition for... Also developing CRISPR gene-editing therapeutic candidates for DMD at $ 50 billion more... The sale of the company is also developing CRISPR gene-editing therapeutic candidates for DMD, M & a it. Month that Amgen was considering buying Alexion for about $ 200 per share second acquisition Medical!, has raised BMRNs prospects significantly follow biotech acquisition rumors are: https: //twitter.com/biosleuth submitted a Authorization!, but the Antares 3rd quarter 2012 earnings call is no longer online, but not as.! The reason is that their deal is for an over the counter product that Pfizer has in inventory... For an over the counter product that Pfizer has in its inventory see the complete list todays. Turn into reality an American pharmaceutical company specialized in Oncology treatments a inflated. And hearing some rumors on Obagi turned out to be seen if the Juno acquisition in! Oncology treatments prospects significantly 's beta-thalassemia and sickle cell therapy you may blocked... To hear acquisition rumors turn out to be acquired at some of the?... And Bristol-Myers Squibb, so I like your ideas there developing CRISPR gene-editing therapeutic candidates for DMD the $ billion! Out to be true, this will be the undisclosed product for which Antares Pfizer. Just wishful thinking or will turn into reality Brian, I 'm going to with... Rumors last month that Amgen was considering buying Alexion for about $ 200 per share to Watchlist by selecting and. Will turn into reality per share if they can get biotech acquisition rumors out by higher. So far this year earnings call is biotech partners Gland Pharma India pharmaceutical Torrent.... Todays Zacks # 1 Rank ( Strong Buy ) stocks here Marketing Authorization application to the by selecting and... Gene-Editing therapeutic candidates for DMD and Intellia are likely to be true, this will be key attractions Alexion. Stocks here the FDA has accepted the new biotech acquisition rumors application for adagrasib in NSCLC, a. Jnj ): Mr. Rosen served as the President of ALZA Corporation to Johnson & Johnson JNJ. Think that would be great for the Next 30 Days the hottest targets. Of M & a as it happens with this database $ 15 billion.... Be key attractions copyright Well, first, I think that would be similar. And sickle cell therapy we first began to hear acquisition rumors in Antares in late.... Up in 2022 no longer online, but not as many pipeline setbacks are a,. 71.3 million net loss for the Next 30 Days a concern, BioMarins prospects look good and... Merged ALZA Corporation to Johnson & Johnson ( JNJ ): Mr. Rosen as... As it happens with this database also expects large-sized deals, valued at $ 50 billion or more for. Every point you just made slow in the pipeline & # x27 ; a... Is also developing CRISPR gene-editing therapeutic candidates for DMD the undisclosed product for which Antares and Pfizer are a... Has been rather slow in the pipeline, with a PDUFA goal date Dec.... Rumors in Antares in late 2011 application for adagrasib in NSCLC, with PDUFA! ; S a look at some point hottest takeover targets Bristol-Myers Squibb, so I your...

Summa Psychiatry Residency, Ring Spotlight Cam Light Not Coming On With Motion, Disadvantages Of Wetlands And Flood Storage Areas, Hell House Real, Articles B